间充质基质细胞治疗眼部自身免疫性疾病
间充质基质细胞(MSC)因免疫调节、易分离扩增、低免疫原性及人体安全可行性,成为眼部自身免疫性疾病的潜在细胞疗法。临床前与早期临床试验提示MSC及其衍生物对自身免疫性葡萄膜炎和干燥综合征相关干眼病有疗效。本综述总结其治疗机制、临床前与临床研究结果,并讨论临床转化挑战与应对策略。
要点
- MSC具备免疫调节、促组织再生、易扩增、低免疫原性等治疗优势。
- 临床前与早期临床试验提示MSC对自身免疫性葡萄膜炎和干燥综合征相关干眼病有疗效。
- MSC疗法的临床转化仍面临挑战,综述提出了相应策略。
核心结论
- MSC及其衍生物在眼部自身免疫性疾病中展现出治疗潜力,但临床转化仍需克服挑战。
研究设计与样本
- 本综述概述MSC治疗机制,并汇总其用于眼部自身免疫性疾病的临床前与临床研究结果。
主要发现
- 临床前与早期临床试验证据提示MSC及其衍生物对自身免疫性葡萄膜炎和干燥综合征相关干眼病有疗效。
临床怎么用
- MSC疗法可作为眼部自身免疫性疾病(如自身免疫性葡萄膜炎、干燥综合征相关干眼病)的潜在细胞治疗选择。
局限性
- MSC疗法的成功临床应用仍面临挑战,综述讨论了应对策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mesenchymal stromal cells, commonly referred to as MSCs, have emerged as a promising cell-based therapy for a range of autoimmune diseases thanks to several therapeutic advantages. Key among these are: 1) the ability to modulate innate and adaptive immune responses and to promote tissue regeneration, 2) the ease of their isolation from readily accessible tissues and expansion at scale in culture, 3) their low immunogenicity enabling use as an allogeneic "off-the-shelf" product, and 4) MSC therapy's safety and feasibility in humans, as demonstrated in more than one thousand clinical trials. Evidence from preclinical studies and early clinical trials indicate the therapeutic potential of MSCs and their derivatives for efficacy in ocular autoimmune diseases such as autoimmune uveoretinitis and Sjögren's syndrome-related dry eye disease. In this review, we provide an overview of the current understanding of the therapeutic mechanisms of MSCs, and summarize the results from preclinical and clinical studies that have used MSCs or their derivatives for the treatment of ocular autoimmune diseases. We also discuss the challenges to the successful clinical application of MSC therapy, and suggest strategies for overcoming them.
引用
- Oh JY, Lee RH. Mesenchymal stromal cells for the treatment of ocular autoimmune diseases. Prog Retin Eye Res. 2021. PMID: 33775824. doi:10.1016/j.preteyeres.2021.100967
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。